Logo.png
Guardion’s Proprietary Medical Device, the MapcatSF®, Receives Patent from the Hong Kong Patents Registry
17 juil. 2019 07h00 HE | Guardion Health Sciences, Inc.
San Diego, CA, July 17, 2019 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (Nasdaq: GHSI), announced that it has received a patent from the Patents Registry in...
Logo.png
Guardion’s Proprietary Medical Device, the MapcatSF®, Receives Patent from the European Union
20 juin 2019 07h00 HE | Guardion Health Sciences, Inc.
San Diego, CA, June 20, 2019 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (Nasdaq: GHSI), an ocular health sciences and technologies company that develops,...
Logo.png
Guardion Launches Second Ocular Health Formula ‘GlaucoCetin’
04 juin 2019 07h00 HE | Guardion Health Sciences, Inc.
In an IRB-approved trial conducted at the New York Eye and Ear Infirmary, the parent compound of GlaucoCetin, GlaucoHealth, designed by Robert Ritch, MD, successfully reversed mitochondrial...
Logo.png
Guardion’s Lumega-Z Formula Associated with Substantial Clinical Improvement in Patients Contrast Sensitivity Visual Function (CSF) vs AREDS 2
09 mai 2019 10h14 HE | Guardion Health Sciences, Inc.
In a recent study presented at the Association for Research in Vision and Ophthalmology (ARVO) 2019 annual meeting, improvements in visual function (CSF) in the Lumega-Z Group were statistically...
Logo.png
Guardion Health Sciences, Inc. Receives Official Trademark Registrations in China
01 mai 2019 07h00 HE | Guardion Health Sciences, Inc.
Guardion’s Lumega-Z product and MapcatSF device are key components of its two-pronged evidence-based protocol for the treatment of a depleted macular protective pigment, a known risk factor for...